Literature DB >> 9343121

Cerebrospinal fluid analysis differentiates between relapsing-remitting and secondary progressive multiple sclerosis.

P J Jongen1, K J Lamers, W H Doesburg, W A Lemmens, O R Hommes.   

Abstract

OBJECTIVES: To find whether CSF analysis may differentiate between relapsing-remitting and secondary progressive multiple sclerosis.
METHODS: In 17 patients with relapsing-remitting and 16 patients with secondary progressive multiple sclerosis, all without current or recent relapses, albumin CSF: peripheral blood ratio, mononuclear cell number, CD4+, CD8+, and B1+ subsets, CD4+:CD8+ ratio, IgG, IgG index, IgM, IgM index, complement components C3 and C4, and C3 and C4 indices, myelin basic protein, neuron specific enolase, S100, and lactate were determined. For each measure the statistical distance measure D2 was calculated. For computation of a discriminant score variables with a P value< or =0.15 were included (two sided univariate t test). These were albumin CSF: peripheral blood ratio, mononuclear cell number, IgM, IgM index, C3, C4, neuron specific enolase, S100, and lactate. Simultaneous distributions of the variables were compared between both groups (multivariate t test) and a discriminant score was computed (linear discriminant analysis).
RESULTS: The discriminant score allocated all 14 relapsing-remitting patients to the relapsing-remitting group (positive score) and 12 of 13 secondary progressive patients to the secondary progressive group (negative score). One secondary progressive patient was allocated to the relapsing-remitting group.
CONCLUSIONS: Patients with relapsing-remitting or secondary progressive multiple sclerosis differ in CSF profile and CSF analysis may help to differentiate between relapsing-remitting and secondary progressive multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9343121      PMCID: PMC2169777          DOI: 10.1136/jnnp.63.4.446

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  37 in total

1.  A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis.

Authors:  M B Bornstein; A Miller; S Slagle; M Weitzman; E Drexler; M Keilson; V Spada; W Weiss; S Appel; L Rolak
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

2.  The longstanding MS lesion. A quantitative MRI and electron microscopic study.

Authors:  D Barnes; P M Munro; B D Youl; J W Prineas; W I McDonald
Journal:  Brain       Date:  1991-06       Impact factor: 13.501

3.  Calibration of fluorescence intensities to quantify antibody binding surface determinants of cell subpopulations by flow cytometry.

Authors:  R Dux; A Kindler-Röhrborn; K Lennartz; M F Rajewsky
Journal:  Cytometry       Date:  1991

4.  Patterns of blood-brain barrier impairment and clinical features in multiple sclerosis.

Authors:  B N McLean; A Z Zeman; D Barnes; E J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-04       Impact factor: 10.154

5.  Histopathology and the blood-cerebrospinal fluid barrier in multiple sclerosis.

Authors:  H Lassmann; G Suchanek; K Ozawa
Journal:  Ann Neurol       Date:  1994       Impact factor: 10.422

6.  The concentration of IgM in the cerebrospinal fluid of neurological patients.

Authors:  C J Sindic; C L Cambiaso; A Depré; E C Laterre; P L Masson
Journal:  J Neurol Sci       Date:  1982-09       Impact factor: 3.181

7.  Intrathecal synthesis of IgG, IgA, IgM and IgD in untreated multiple sclerosis and controls.

Authors:  F Lolli; I Halawa; H Link
Journal:  Acta Neurol Scand       Date:  1989-09       Impact factor: 3.209

8.  CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high-dose intravenous methylprednisolone.

Authors:  S T Frequin; F Barkhof; K J Lamers; O R Hommes; G F Borm
Journal:  Acta Neurol Scand       Date:  1992-09       Impact factor: 3.209

9.  Age-related changes of neuron-specific enolase, S-100 protein, and myelin basic protein concentrations in cerebrospinal fluid.

Authors:  B G van Engelen; K J Lamers; F J Gabreels; R A Wevers; W J van Geel; G F Borm
Journal:  Clin Chem       Date:  1992-06       Impact factor: 8.327

10.  Humoral and cellular immunologic study of cerebrospinal fluid in a patient with Behçet encephalitis.

Authors:  P J Jongen; H E Daelmans; B Bruneel; M R den Hartog
Journal:  Arch Neurol       Date:  1992-10
View more
  7 in total

1.  Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression.

Authors:  William T Regenold; Pornima Phatak; Michael J Makley; Roger D Stone; Mitchel A Kling
Journal:  J Neurol Sci       Date:  2008-09-09       Impact factor: 3.181

2.  Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions.

Authors:  Andrew A Kanner; Nicola Marchi; Vincent Fazio; Marc R Mayberg; Michael T Koltz; Vitaly Siomin; Glen H J Stevens; Thomas Masaryk; Barbara Aumayr; Barbara Ayumar; Michael A Vogelbaum; Gene H Barnett; Damir Janigro
Journal:  Cancer       Date:  2003-06-01       Impact factor: 6.860

3.  Cerebrospinal fluid S-100 protein levels in neurological pathologies.

Authors:  J R Infante; A Martínez; J Ochoa; F Cañadillas; M Torres-Avisbal; J A Vallejo; F M González; C Pacheco; J M Latre
Journal:  J Physiol Biochem       Date:  2003-12       Impact factor: 4.158

4.  Cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis.

Authors:  Irena Dujmovic
Journal:  Mult Scler Int       Date:  2011-05-02

Review 5.  Chicken-or-egg question: Which came first, extracellular vesicles or autoimmune diseases?

Authors:  Federica Maione; Giuseppe Cappellano; Mattia Bellan; Davide Raineri; Annalisa Chiocchetti
Journal:  J Leukoc Biol       Date:  2020-02-28       Impact factor: 4.962

6.  Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients.

Authors:  Sven Jarius; Hannah Pellkofer; Nadja Siebert; Mirjam Korporal-Kuhnke; Martin W Hümmert; Marius Ringelstein; Paulus S Rommer; Ilya Ayzenberg; Klemens Ruprecht; Luisa Klotz; Nasrin Asgari; Tobias Zrzavy; Romana Höftberger; Rafik Tobia; Mathias Buttmann; Kai Fechner; Kathrin Schanda; Martin Weber; Susanna Asseyer; Jürgen Haas; Christian Lechner; Ingo Kleiter; Orhan Aktas; Corinna Trebst; Kevin Rostasy; Markus Reindl; Tania Kümpfel; Friedemann Paul; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2020-09-03       Impact factor: 8.322

7.  Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients.

Authors:  Sven Jarius; Christian Lechner; Eva M Wendel; Matthias Baumann; Markus Breu; Mareike Schimmel; Michael Karenfort; Adela Della Marina; Andreas Merkenschlager; Charlotte Thiels; Astrid Blaschek; Michela Salandin; Steffen Leiz; Frank Leypoldt; Alexander Pschibul; Annette Hackenberg; Andreas Hahn; Steffen Syrbe; Jurgis Strautmanis; Martin Häusler; Peter Krieg; Astrid Eisenkölbl; Johannes Stoffels; Matthias Eckenweiler; Ilya Ayzenberg; Jürgen Haas; Romana Höftberger; Ingo Kleiter; Mirjam Korporal-Kuhnke; Marius Ringelstein; Klemens Ruprecht; Nadja Siebert; Kathrin Schanda; Orhan Aktas; Friedemann Paul; Markus Reindl; Brigitte Wildemann; Kevin Rostásy
Journal:  J Neuroinflammation       Date:  2020-09-03       Impact factor: 8.322

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.